The top after-market NASDAQ stock market gainers are: Hauppauge Digital, BioScrip, Titan Machinery, OmniVision Technologies, Parexel International, Zumiez, Sanmina-SCI, Cyberonics, Spectrum Pharmaceuticals, and ICAgen.
Hauppauge Digital Inc. (HAUP) surged 5.58 percent to $2.84 in the after-market trading.
BioScrip Inc. (BIOS) soared 4.95 percent to $4.24 in the after-hours session.
Titan Machinery, Inc. (TITN) improved 4.90 percent to $22.01 in the after-market trading.
OmniVision Technologies Inc. (OVTI) jumped 4.31 percent to $29.51 in the after-hours session. The company's second quarter adjusted earnings were $34.2 million or 58 cents a share, up from $14.3 million or 27 cents a share last year. Revenue rose to $239.5 million from $183.3 million. Analysts had expected profit of 52 cents a share on revenue of $231.21 million.
OmniVision expects third quarter adjusted earnings of 50 cents to 63 cents a share and revenue of $230 million to $250 million. Analysts expect profit of 42 cents a share on revenue of $211.17 million.
Parexel International Corp. (PRXL) climbed 4.06 percent to $18.31 in the after-market trading.
Zumiez, Inc. (ZUMZ) rose 3.74 percent to $33 in the after-hours session.
Sanmina-SCI Corp. (SANM) grew 3.48 percent to $10.81 in the after-market trading.
Cyberonics Inc. (CYBX) gained 2.89 percent to $27.69 in the after-hours session.
Spectrum Pharmaceuticals, Inc. (SPPI) increased 2.79 percent to $4.57 in the after-market trading. The company said its board unanimously approved Spectrum's entry into a replacement rights agreement that will extend until Dec. 13, 2020 the framework of the current stockholder rights plan.
Spectrum said a stockholder rights agreement will not prevent takeovers at a full and fair price, but rather is designed to deter coercive takeover tactics and to encourage anyone attempting to acquire Spectrum to first negotiate with the board.
ICAgen Inc. (ICGN) moved up 2.75 percent to $2.24 in the after-hours session. The company and Pfizer now selected a compound into further clinical studies for advancement in sodium ion channel Nav1.7 as a pain treatment. The selection of this compound has triggered a milestone payment to Icagen of $1.0 million.